The product is the generic equivalent to Baxter Healthcare’s Mesnex Injection.
Mylan has begun shipping the generic drug, which has been approved by the US Food and Drug Administration.
Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis, which had US sales of approximately $11.7m for the 12 months ending 31 December 2011, according to IMS Health.